They said previous research suggested COX-1 and COX-2 inhibitors may be responsible for the inhibition of intestinal prostaglandin synthesis.
The authors also noted that wide variations in the definition of disease exacerbation may have contributed to the heterogeneity of the studies included, and that there may have been confounding by the indication for acetaminophen and NSAID use.
“We recognise that IBD is a heterogeneous disease and therefore, there may be subgroups of patients particularly at risk of disease exacerbations with use of NSAIDs.”
One author was supported by the American Gastroenterological Association and by the National Institute of Diabetes and Digestive and Kidney Diseases, and declared consulting and research funding from the pharmaceutical industry. No other conflicts of interest were declared.
SOURCE: Moninuola O et al. Aliment Pharmacol Ther. 2018 Apr 5. doi: 10.1111/apt.14606.